Cargando…
Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease
BACKGROUND: Fabry disease is a lysosomal X-linked enzyme deficiency of α-galactosidase A associated with an increased mortality and morbidity due to renal failure, cardiac disease and early onset stroke. METHODS: We examined the functional blood flow response of the brain after visual stimulation (r...
Autores principales: | Moore, David F, Altarescu, Gheona, Herscovitch, Peter, Schiffmann, Raphael |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC116601/ https://www.ncbi.nlm.nih.gov/pubmed/12079501 http://dx.doi.org/10.1186/1471-2377-2-4 |
Ejemplares similares
-
Arterial Wall Properties and Womersley Flow in Fabry Disease
por: Moore, David F, et al.
Publicado: (2002) -
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
por: Schiffmann, Raphael, et al.
Publicado: (2009) -
Detection of single nucleotide and copy number variants in the Fabry disease-associated GLA gene using nanopore sequencing
por: Nowak, Albina, et al.
Publicado: (2021) -
An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy
por: Goker-Alpan, Ozlem, et al.
Publicado: (2016) -
Recurrent Cerebrovascular Complications under Enzyme Replacement Therapy in a Patient with Fabry Disease on Peritoneal Dialysis
por: Muto, Reiko, et al.
Publicado: (2022)